Full View

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study

SY Smith-Apeldoorn, JKE Veraart, HG Ruhé… - BJPsych …, 2022 - cambridge.org
BackgroundIntravenous infusion of ketamine can produce rapid and large symptom
reduction in patients with treatment-resistant depression (TRD) but presents major obstacles …
被引用次数：10 相关文章

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study

SY Smith-Apeldoorn, JKE Veraart, HG Ruhé… - BJPsych Open, 2022 - research.rug.nl
BACKGROUND: Intravenous infusion of ketamine can produce rapid and large symptom
reduction in patients with treatment-resistant depression (TRD) but presents major obstacles …
[PDF] ru.nl

[PDF][PDF] Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study

SY Smith-Apeldoorn, JKE Veraart, HG Ruhé, MAH Rot… - 2021 - repository.ubn.ru.nl
Background Intravenous infusion of ketamine can produce rapid and large symptom
reduction in patients with treatment-resistant depression (TRD) but presents major obstacles …
[HTML] nih.gov

[HTML][HTML] Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study

SY Smith-Apeldoorn, JKE Veraart, HG Ruhé… - BJPsych …, 2022 - ncbi.nlm.nih.gov
Background Intravenous infusion of ketamine can produce rapid and large symptom
reduction in patients with treatment-resistant depression (TRD) but presents major obstacles …

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study

SY Smith-Apeldoorn, JKE Veraart, HG Ruhé… - BJPsych …, 2022 - search.proquest.com
Background Intravenous infusion of ketamine can produce rapid and large symptom
reduction in patients with treatment-resistant depression (TRD) but presents major obstacles …

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study

SY Smith-Apeldoorn, JKE Veraart, HG Ruhé… - BJPsych …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Intravenous infusion of ketamine can produce rapid and large symptom
reduction in patients with treatment-resistant depression (TRD) but presents major obstacles …

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study.

SY Smith-Apeldoorn, JKE Veraart, HG Ruhé… - Bjpsych …, 2021 - europepmc.org
Background Intravenous infusion of ketamine can produce rapid and large symptom
reduction in patients with treatment-resistant depression (TRD) but presents major obstacles …